London biotech secures £90 million backing
Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers
Myricx Bio’s £90 million Series A fundraising will initially focus on developing its work treating solid tumours, such as breast and gastric cancers, but potentially can apply across all cancers